louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02691715: Intrauterine Saline Washing for Detection Endometrial Disease in Patients With Abnormal Uterine Bleeding
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Endometrial Disease
Lead sponsor: Zeynep Kamil Maternity and Pediatric Research and Training Hospital
Sponsor class: OTHER
First posted: 2016-02-25
Enrollment: 400
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Investigator will examined the diagnostic effect of the endometrial washing by saline. Because this technique more less painful and easier compared to endometrial curettage. Participants will separate into two groups. In study groups before endometrial curettage 5 cc saline infused to the endometrial cavity then aspirate and put into thin prep to examined. After this procedure routine endometrial curettage will be done. In control group only endometrial curettage will be done. Pathologic results of thin prep and curettage will compared.


Eligibility criteria: Inclusion Criteria:

* Abnormal uterine bleeding

Exclusion Criteria:

* Involuntary, under 35 years old,

Primary outcomes:
measure: Cervical cytological results according to Bethesda 2003
timeFrame: 1 month
measure: Endometrial hyperplasiz classification according to World Health Organization 2013
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Zeynep Kamil Maternity and Pediatric Research and Training Hospital
Study officials:
References:
citation: Moschos E, Ashfaq R, McIntire DD, Liriano B, Twickler DM. Saline-infusion sonography endometrial sampling compared with endometrial biopsy in diagnosing endometrial pathology. Obstet Gynecol. 2009 Apr;113(4):881-887. doi: 10.1097/AOG.0b013e31819b3fc7.
citation: Rotenberg O, Renz M, Reimers L, Doulaveris G, Gebb J, Goldberg GL, Dar P. Simultaneous endometrial aspiration and sonohysterography for the evaluation of endometrial pathology in women aged 50 years and older. Obstet Gynecol. 2015 Feb;125(2):414-423. doi: 10.1097/AOG.0000000000000631.
citation: Bese T, Demirkiran F, Guralp O, Sanioglu C, Arvas M. Transtubal transport of carcinoma cells into the peritoneal cavity after saline infusion via transcervical route in patients with endometrial carcinoma. Int J Gynecol Cancer. 2009 May;19(4):682-5. doi: 10.1111/IGC.0b013e3181a48c7f.
Clinical trial NCT02947815: Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
Official title: A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase II/III Clinical Trial to Compare the Safety and Efficacy of NABOTA Versus BOTOX in Treatment of Essential Blepharospasm
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Blepharospasm
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2016-10-28
Enrollment: 234
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the Efficacy and Safety of NABOTA in treatment of essential blepharospasm


Eligibility criteria: Inclusion Criteria:

* Male of female of at least 18 years old
* Grade 2\~4 in Scott's scale

Primary outcomes:
measure: The change from baseline in Scott's Scale Score
timeFrame: At 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: the catholic university of korea, Seoul ST. Mary's Hospital.
Study officials:
References:
Clinical trial NCT03509415: Reflectance Confocal Microscopy to Diagnose BCC
Official title: Reflectance Confocal Microscopy to Diagnose Basal Cell Carcinoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Basal Cell Carcinoma
Keywords: Confocal
RCM
Imaging
Skin cancer
Lead sponsor: Skin Care Network Ltd.
Sponsor class: INDUSTRY
First posted: 2018-04-26
Enrollment: 324
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting at a skin cancer clinic with a lesion that is clinically suspicious for BCC

Brief summary: It is proposed to undertake a study to determine the diagnostic utility of using RCM for the diagnosis of Basal Cell Carcinoma (BCC) in a tertiary referral centre as outlined by the recent NICE report (Nov 2015). This will allow an assessment of the potential to avoid diagnostic biopsy within the treatment pathway.

Detailed description: Study Design This is an observational, non-randomised, non-controlled, prospective cohort study to look at the efficacy of in vivo RCM as a diagnostic tool in the diagnosis of BCC.

Study Hypothesis The hypothesis of this study is that the use of RCM is would enable a reduction in the number of diagnostic biopsies taken before definitive treatment of BCC by at least 50%.

The secondary hypothesis is that the intra- \& inter-observer agreement for interpreting the RCM images will have kappa scores 0.6 or greater (indicating good agreement).

Patients will be recruited from the outpatient clinic of Skin Care Network London.

Eligibility criteria: Inclusion Criteria:

1. Age 18 years or older
2. Patient suspected of having a primary basal cell carcinoma that is a candidate for surgical treatment.
3. Patient willing and able to give informed consent

Exclusion Criteria:

1. Recurrent or other higher-risk BCC
2. Patient with basal cell naevus syndrome
3. Patient treated with hedgehog inhibitor medication (vismodegib)
4. Patient not suitable for diagnostic biopsy
5. Location of lesion unsuitable, inaccessible or impractical for scanning with RCM as determined by investigator
6. Patient with co-morbidities such as other skin disease

Primary outcomes:
measure: Sensitivity and Specificity
timeFrame: During exam (biopsy results typically available within one week).
Secondary outcomes:
measure: intra- & inter-observer agreement for interpreting the RCM images
timeFrame: 6 months
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Skin Care Network Barnet Ltd
Study officials:
affiliation: Skin Care Network Ltd.
name: Howard Stevens, MA PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06972537: A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia
Official title: Model-Guided Dose Optimization vs. Empirical Dosing of Piperacillin-Tazobactam in the Treatment of Pneumonia in Elderly Patients: A Study on Superiority
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pneumonia
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2025-05-15
Enrollment: 42
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Pneumonia is characterized by high incidence and mortality rates in elderly patients (≥65 years old). Piperacillin-tazobactam, as a broad-spectrum antibiotic, has its therapeutic efficacy and safety potentially influenced by the infusion regimen. However, research on infusion regimens specifically targeting the elderly population is currently limited. In our preliminary dose simulation, under the pharmacokinetic/pharmacodynamic (PK/PD) target of achieving a free drug concentration time percentage above 100% of the minimum inhibitory concentration (fT%\>100% MIC), the regimen of administering the drug every 6 hours (q6h) achieved a concentration compliance rate of 90% within 4 hours. This study aims to explore the differences between two infusion modes (q6h for 4 hours vs. q8h for 3 hours) and to provide preliminary evidence for clinical practice.


Eligibility criteria: Inclusion Criteria:

Age must be greater than 65 years Clinical diagnosis of Pneumonia Receiving intravenous piperacillin-tazobactam treatment

Exclusion Criteria:

History of allergy to β-lactam antibiotics Continuous renal replacement therapy, severe organ dysfunction Malignant tumor disease

Primary outcomes:
measure: Clinical improvement rate
timeFrame: 3 months
Secondary outcomes:
measure: PK/PD target attainment rate
timeFrame: 2 days
measure: 28-day mortality rate
timeFrame: 3 months
measure: 7-day microbiological clearance rate
timeFrame: after 7days when finished infuse piperacillin
measure: Length of Hospital Stay ICU and Length of ICU Stay
timeFrame: Up to 24 weeks
Other outcomes:
Locations:
city: Jinan
country: China
facility: Second hospital of Shandong university
state: Shandong
Study officials:
References:
Clinical trial NCT05255237: Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
Official title: A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Alopecia Areata
Lead sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2022-02-24
Enrollment: 315
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".


Eligibility criteria: Inclusion Criteria:

* Subjects voluntarily sign the informed consent form.
* Patients who participated in ZGJAK018.

Exclusion Criteria:

* Subjects who are unsuitable to the trial, as identified by the investigator.

Primary outcomes:
measure: Number of subjects reporting treatment-emergent adverse events
timeFrame: Baseline through week 24
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: 11 Xizhimen South Street
state: Beijing
Study officials:
affiliation: Peking University People's Hospital
name: Jianzhong Zhang, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital for skin diseases, Chinese Academy of Medical Sciences
name: Qianjin Lu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04271137: Correction of Enophthalmos and Orbital Volume Using Pre-bent Mesh Versus 3d Printed Onlay in Orbital Fracture Cases
Official title: Evaluation of Orbital Reconstruction Using Patient Specific 3-D Printed Onlay Versus Pre-Bent Titanium Mesh
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Orbital Fractures
Enophthalmos
Periorbital Fracture
Keywords: 3d printed onlay
PEEK
orbital mesh
computer-guided surgery
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-02-17
Enrollment: 20
Sex: ALL
Minimum age (years): 17
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: this study evaluates the post-surgical correction of enophthalmos and orbital volume using 3D printed only versus pre-bent titanium mesh in blow-out fracture cases

Detailed description: Many materials had been used in reconstruction of blow out fractures, the aim of this study is to evaluate the enophthalmos correction and orbital volume restoration using 3D printed onlay versus pre-bent titanium mesh

Eligibility criteria: Inclusion Criteria:

* Adult patients (≤17 years old).
* Blow-out Orbital Fracture.
* Unilateral Orbital Trauma.
* Enophthalmos (≤ 2 mm).
* Patients with contralateral healthy, non-surgically operated orbit.

Exclusion Criteria:

* Young Patients (\> 17 years old).
* Patients with Systemic diseases.
* Bilateral Orbital Trauma.
* Enophthalmos (\>2 mm).
* Patients whom cannot tolerate follow up intervals.

Primary outcomes:
measure: Enophthalmos
timeFrame: 1 week post-operative
measure: Enophthalmos
timeFrame: 1 year post-operative
Secondary outcomes:
measure: Orbital volume
timeFrame: one week post-operative
measure: Implant position accuracy
timeFrame: One week post-operative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry - Cairo University
Study officials:
affiliation: Cairo University
name: Ahmed Mohamed, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00278837: Avon Foundation Program to Improve Quality of Life in Breast Cancer Survivors
Official title: Contemplative Self-Healing to Improve Quality of Life in Breast Cancer Survivors: the Avon Foundation Program to Reach Medically Underserved Populations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: Meditation
Stress-reduction
Cognitive-affective behavior learning
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
Collaborators: name: Avon Foundation
First posted: 2006-01-18
Enrollment: 94
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 101
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Women with breast cancer often suffer significant distress and disability from their disease. A practice of meditation-based stress reduction and cognitive-affective-behavioral learning may help women with breast cancer decrease their suffering and improve their quality of life.

Detailed description: The objective of this study in women recently treated for breast cancer is to determine whether an intervention program consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning has the potential for reducing disabling distress and improving quality of life in a population vulnerable to the progression or recurrence of disease. Quality of life will be assessed at 12 months.

Eligibility criteria: Inclusion Criteria:

All women with stage I-III breast cancer who have received treatment within the preceding year will be eligible for inclusion in the study.

Exclusion Criteria:

1. Patients who refuse to participate will be excluded
2. Patients with metastatic (stage IV) cancer are excluded.

Primary outcomes:
measure: Quality of life will be assessed by within patient differences in the FACT-G (General Functional Assessment of Cancer Treatment Scale), as well as with the disease specific subscales at baseline and at 12 months.
timeFrame: Subjects will complete questionnaires at baseline and closeout. Patients will participate in the meditation program weekly for 20 weeks.
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: The New York Presbyterian Hospital-Weill Medical Center
state: New York
Study officials:
affiliation: Weill Medical College of Cornell
name: Mary E Charlson, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Weill Medical College of Cornell University, Center for Complementary and Integrative Medicine
name: Joseph Loizzo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Charlson ME, Loizzo J, Moadel A, Neale M, Newman C, Olivo E, Wolf E, Peterson JC. Contemplative self healing in women breast cancer survivors: a pilot study in underserved minority women shows improvement in quality of life and reduced stress. BMC Complement Altern Med. 2014 Sep 23;14:349. doi: 10.1186/1472-6882-14-349.
Clinical trial NCT05363137: Effectiveness of Using a Chatbot to Promote Adherence to Home Physiotherapy
Official title: Herramienta De Procesamiento De Lenguaje Natural En Dispositivo Móvil Inteligente Para Fomentar La Adherencia a La Rehabilitación Domiciliaria
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: University of Valencia
Sponsor class: OTHER
Collaborators: name: Ministerio de Ciencia e Innovación, Spain
First posted: 2022-05-05
Enrollment: 65
Sex: ALL
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Chatbot oriented to virtually assist patients in a physiotherapy treatment has been designed and developed to interact with patients with musculoskeletal disorders in need for domiciliary rehabilitation. The tool has been designed to promote adherence to rehabilitation, what in turn may have an impact on clinical outcome. A randomized clinical trial involving patients undergoing total knee replacement has bee designed to determine the applicability of the proposal. The participants will be assigned into exerimental group (intervention with the software tool) or control group (standard care).


Eligibility criteria: Inclusion Criteria:

* Individuals on the waiting list for total knee replacement surgery
* Undergoing primary total knee replacement surgery
* Who have a personal smartphone
* Who have an instant messaging application installed
* Familiar with the use of such application (more than 3 accesses per week),

Exclusion Criteria:

* Evident cognitive state that prevents to understand care provider instructions
* Vestibular or central nervous system affection (e.g. stroke)
* Cannot read or write
* Do not understand Spanish language
* Not able to consent to participate

Primary outcomes:
measure: Adherence
timeFrame: Change from baseline to 3 months after surgery date
Secondary outcomes:
measure: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
timeFrame: Change from baseline to 3 months and one year after surgery date
measure: Knee Pain
timeFrame: Change from baseline to 3 months and one year after surgery date
Other outcomes:
measure: Safety
timeFrame: Baseline (surgery day) to 12 months
measure: Feasibility_1
timeFrame: Time from initial day to last day of recruitment up to two years
measure: Feasibility_2
timeFrame: Time from initial day to 3 months after surgery date
measure: International Physical Activity Questionnaire (IPAQ-E)
timeFrame: Change from baseline to 3 months after surgery date
measure: System Usability
timeFrame: Change from baseline to 3 months after surgery date
Locations:
city: Valencia
country: Spain
facility: Hospital La Fe
Study officials:
References:
Clinical trial NCT04093037: Analysis of the Diagnostic Performance of LacryDiag, a New Analyzer of the Ocular Surface in the Dry Eye
Official title: Analysis of the Diagnostic Performance of LacryDiag, a New "All-in-one" Non-contact Analyzer of the Ocular Surface in the Dry Eye. Study LACRYMOSA
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye
Keywords: Dry eye
LacryDiag
Fluorescein
Break-Up Time (BUT)
Schirmer test
Lacrimal film
Oxford score
Meibomian Gland
Tear Meniscus (TM)
Non Invasive Break-Up Time (NIBUT)
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2019-09-17
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: 80 patients divided into 4 subgroups according to the value of manual Standard Break-Up-Time (SBUT):

* 0-5 seconds (very dry)
* 5-10 seconds (sec)
* 10-15 seconds (moderately dry)
* 15-20 seconds (normal)
Primary purpose: DIAGNOSTIC

Brief summary: LacryDiag is a new Conformity European (CE) marked diagnostic imaging device devoted to the analysis of the ocular surface. It is an "all in one" device that provides 4 data: non-invasive break-up time (Non-Invasive Break-Up-Time (NIBUT) without fluorescein eye drop); height of the Tear Meniscus (TM); an infrared image of the meibomian glands; a picture of the lacrimal film by interferometry. it's performance will be compare between in diagnosing dry eye syndrome with the standard clinical evaluation, in 80 patients suffering from dry eye diseases and followed at the consultation of the Ophthalmology department of the University Hospital of Saint-Etienne.

Detailed description: The primary purpose of this study is to compare the value of Break-Up-Time (BUT) between Non-Invasive Break-Up-Time (NIBUT) measured by LacryDiag and Standard Break-Up-Time (SBUT) measured by usual practice.

Eligibility criteria: Inclusion Criteria:

* Affiliates or beneficiaries of social security scheme
* With Dry eye of any cause, diagnosed with conventional means
* Signed informed consent

Exclusion Criteria:

* Major blepharospasm
* Serious illness preventing participation according to investigator
* Allergy to fluorescein
* Pregnant or / and breastfeeding women
* Under guardianship, curatorship or safeguard of justice
* Unable to express their consent
* Person in emergency situation

Primary outcomes:
measure: Break-Up-Time (BUT)
timeFrame: Day: 1
Secondary outcomes:
measure: Standard Break-Up Time (SBUT)
timeFrame: Day: 1
measure: MicroInstillation Break-Up Time (MIBUT)
timeFrame: Day: 1
measure: Tear Meniscus (TM) height and Schirmer test
timeFrame: Day: 1
measure: Percentage loss of Meibomian Gland.
timeFrame: Day: 1
measure: Thickness (in nanometer) and regularity of lacrimal film (type)
timeFrame: Day: 1
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: Chu Saint-Etienne
Study officials:
affiliation: CHU SAINT-ETIENNE
name: Gilles THURET, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05580237: Pressure Gradient vs. Flow Relationships in Patients With Symptomatic Valvular Aortic Stenosis
Official title: Pressure Gradient vs. Flow Relationships in Patients With Symptomatic Valvular Aortic Stenosis - a Comparison Between High- and Low Gradient Subtypes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aortic Valve Stenosis
Lead sponsor: Aarhus University Hospital Skejby
Sponsor class: OTHER
First posted: 2022-10-14
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with suspected severe AS scheduled for evaluation for aortic valve intervention

Brief summary: The objective of the present study is to investigate to hemodynamic profile at rest and during peak exercise of patients with suspected severe aortic stenosis and to compare flow- and pressure changes between high gradient patients and low gradient patients.


Eligibility criteria: Inclusion Criteria:

* Patients with suspected severe AS scheduled for evaluation for aortic valve intervention:
* LVEF \> 50 %
* AVA \< 1.0 cm2
* Symptomatic - at least equivalent to NYHA functional class II

Exclusion Criteria:

* Congenital heart disease
* Severe coronary artery disease (main stem, proximal LAD or 3 vessel disease)
* Moderate or severe aortic valve regurgitation
* Moderate or severe mitral valve regurgitation or stenosis
* Moderate or severe pulmonary valve regurgitation or stenosis
* Moderate or severe tricuspid valve regurgitation or stenosis
* Severe pulmonary hypertension (tricuspid valve pressure gradient of 60 mmHg)
* Right ventricular dysfunction (TAPSE \< 17 mm)
* Restrictive cardiomyopathy or cardiac amyloidosis
* Constrictive pericarditis
* Inability to perform supine bicycle exercise

Primary outcomes:
measure: Pressure and flow relationships across the aortic valve during rest and during supine exercise
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Aarhus University Hospital
Study officials:
affiliation: Department of Cardiology, Aarhus University Hospital
name: Henrik Vase, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: